Sarfaraz K. Niazi, PhD, outlines how President Joe Biden's new budget for 2025 could impact biosimilars, including provisions to clear up confusion surrounding interchangeable products.
Image credit: utah51 - stock.adobe.com
The FY 2025 US budget announced on March 11 is one of the rare admissions of why the cost of pharmaceuticals per capita is the highest globally. The FY 2025 budget includes several legislative proposals supporting the FDA's efforts to protect American consumers and patients. Of the dozens of proposals, the significant ones for the generic industry are:
The extension of the ingredient listing requirement of parenteral products to chemical drugs.
Amending certain exclusivity provisions for drugs to encourage meaningful innovation and timely competition. FDA is seeking to encourage competition for new drugs by proposing to amend the Hatch-Waxman 3-year exclusivity provisions to ensure that this exclusivity is limited to situations where the new drug applicant is seeking such exclusivity and where the data supporting the exclusivity demonstrates the hypothesized effect of the drug and to prevent information on new safety risks from blocking competition. This approach would continue to reward innovation while allowing earlier access to generic drugs in certain situations.
However, the most relevant suggestion is to eliminate the statutory distinction between the approval standard for biosimilar and interchangeable biosimilar products and deem approved biosimilars interchangeable. The statutory distinction between biosimilars and interchangeable biosimilars has led to confusion and misunderstanding among patients and health care providers about the safety and effectiveness of biosimilars and whether interchangeable biosimilars are safer or more effective than other biosimilars. This proposal would make the US biosimilar program more consistent with current scientific understanding and the approach adopted by other major regulatory jurisdictions, such as the European Union, where biosimilars are interchangeable with their respective reference products upon approval. Further, this proposal is expected to increase the uptake of biosimilars, with potential downstream effects of increasing competition, access, and affordability.
However, the FDA is taking a different approach when FDA Commissioner Robert Califf, MD, said approval from Congress is still the best pathway to making the change than just declaring biosimilars interchangeable; the FDA is seeking to amend section 351 of the Public Health Service Act to no longer include a separate statutory standard for a determination of interchangeability and to deem all approved biosimilars to be interchangeable with their respective reference products. This is a wrong decision by the FDA, since such legislative changes are difficult to achieve, and often get tossed out due to many conflicts of interest. Notably, the US Senate has a bill pending to do just that, and I have provided support through my publications and meetings with senators, but it is going nowhere. Before the release of the FY 2025 budget, I was consulted by the White House, and I was able to present a solid scientific argument, avoiding cost savings as the primary reason. I am glad to see this provision in the budget, but I am not sure if the FDA fully supports it and instead waits for the amendment to 351(k), and indeed, the big pharma has already launched a campaign to prevent this from happening.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: How Developers Can Expand Their Monoclonal Antibody Biosimilar Portfolio
March 24th 2025Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and technological feasibility, whereas other biologics encounter development challenges but may see increased adoption as regulatory frameworks advance.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.